These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16637784)

  • 21. Perspectives on dyslipidemia and coronary heart disease in women: an update.
    Bittner V
    Curr Opin Cardiol; 2006 Nov; 21(6):602-7. PubMed ID: 17053411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nurse-led risk assessment/management clinics reduce predicted cardiac morbidity and mortality in claudicants.
    Hatfield J; Gulati S; Abdul Rahman MN; Coughlin PA; Chetter IC
    J Vasc Nurs; 2008 Dec; 26(4):118-22. PubMed ID: 19022170
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic analysis of treatments reducing coronary heart disease mortality in England and Wales, 2000-2010.
    Fidan D; Unal B; Critchley J; Capewell S
    QJM; 2007 May; 100(5):277-89. PubMed ID: 17449875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Arterial hypertension and the kidney].
    Niang A
    Dakar Med; 2008; 53(1):1-6. PubMed ID: 19102111
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevalence of dyslipidemia and general ineffectiveness of its treatment in both primary and secondary prevention of coronary heart disease within family medicine framework--results of LIPIDOGRAM 2005--a nationwide epidemiological study. Dyslipidemia in Poland--ineffective treatment.
    Konduracka E; Jóźwiak J; Mastej M; Lukas W; Tykarski A; Szczepaniak-Chicheł L; Piwowarska W
    Przegl Lek; 2008; 65(12):834-7. PubMed ID: 19441674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents.
    Alsheikh-Ali AA; Lin JL; Abourjaily P; Ahearn D; Kuvin JT; Karas RH
    Am J Cardiol; 2006 Nov; 98(9):1231-3. PubMed ID: 17056335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heartwatch: a secondary prevention programme in primary care in Ireland.
    Bennett K; Jennings S; Collins C; Boland M; Leahy J; Bedford D; Shelley E
    Eur J Cardiovasc Prev Rehabil; 2008 Dec; 15(6):651-6. PubMed ID: 19177599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treating hypertriglyceridemia.
    Röggla G; Fasan M; Kapiotis S
    CMAJ; 2007 Sep; 177(6):603; author reply 604-5. PubMed ID: 17846444
    [No Abstract]   [Full Text] [Related]  

  • 29. On the road to better dyslipidemia outcomes.
    Hughes S
    Nurse Pract; 2009 Feb; 34(2):14-21; quiz 22. PubMed ID: 19155874
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevalence and treatment of dyslipidemia in Canadian primary care: a retrospective cohort analysis.
    Petrella RJ; Merikle E; Jones J
    Clin Ther; 2007 Apr; 29(4):742-50. PubMed ID: 17617298
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease.
    Sigvant B; Wiberg-Hedman K; Bergqvist D; Rolandsson O; Wahlberg E
    Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):39-46. PubMed ID: 19237996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of dyslipidemia with statins in the patient with peripheral arterial disease.
    Blum AS
    Tech Vasc Interv Radiol; 2006 Jun; 9(2):50-5. PubMed ID: 17482100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Coronary heart disease risk factors in Croatia and worldwide: results of the Interheart study].
    Carević V; Rumboldt M; Rumboldt Z;
    Acta Med Croatica; 2007 Jun; 61(3):299-306. PubMed ID: 17629106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral arterial disease: a review of disease awareness and management.
    Watson K; Watson BD; Pater KS
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):365-79. PubMed ID: 17296541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viewpoint: Terje R. Pedersen, MD, PhD. Interview by Robert Short.
    Pedersen TR
    Circulation; 2007 Mar; 115(12):f51-2. PubMed ID: 17393574
    [No Abstract]   [Full Text] [Related]  

  • 36. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease.
    Mancini GB; Etminan M; Zhang B; Levesque LE; FitzGerald JM; Brophy JM
    J Am Coll Cardiol; 2006 Jun; 47(12):2554-60. PubMed ID: 16781387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of cardiovascular events in diabetes.
    Sigal R; Malcolm J; Arnaout A
    Clin Evid; 2006 Jun; (15):623-45. PubMed ID: 16973029
    [No Abstract]   [Full Text] [Related]  

  • 38. The CARI guidelines. Prevention of progression of kidney disease.
    Harris D; Thomas M; Johnson D; Nicholls K; Gillin A;
    Nephrology (Carlton); 2006 Apr; 11 Suppl 1():S2-197. PubMed ID: 16684077
    [No Abstract]   [Full Text] [Related]  

  • 39. A practical approach to reducing cardiovascular risk factors.
    Fonarow GC
    Rev Cardiovasc Med; 2007; 8 Suppl 4():S25-36. PubMed ID: 17934391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, recognition and treatment of cardiovascular risk factors in outpatients with atherothrombosis in Israel.
    Barski L; Porath A; Novack V; Jotkowitz A
    Isr Med Assoc J; 2007 May; 9(5):376-9. PubMed ID: 17591377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.